Please join us to discuss the indications for PARP inhibitors for ovarian cancer, including maintenance versus treatment. We will explore the role of bevacizumab in ovarian cancer treatment, including platinum sensitive and resistant disease and maintenance. We will delve deeper into novel therapeutics for ovarian cancer, including immunotherapy and antibody drug conjugates.

Speaker: Debra Richardson, MD

Recorded in February 2018.

Keywords:  Clinical practice, Ovary, Pharmacology, PARPi, Immunotherapy, Targeted, Maintenance therapy